Optimizing Frontline Immunotherapy in Advanced Non-Small Cell Lung Cancer: Program Highlights

Activity Overview

This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.

0.75 CE Credit(s)
Expires: April 7, 2023

Target Audience

This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

Upon completion of this activity, participants should be better able to:

  • Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
  • Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC

Activity Faculty

Maria E. Arcila, MD

Maria E. Arcila, MD

Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY

Jared M. Weiss, MD

Jared M. Weiss, MD

Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC

Jason M. Chang, MD

Jason M. Chang, MD

Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources